Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Pathologic Immune Pathways in Psoriasis are Rapidly Attenuated by Tofacitinib Treatment: A Randomized Phase 2 Study in Patients with Moderate to Severe Psoriasis
PubMed Similar studies Analyze with GEO2R
Shrinking the Psoriasis assessment gap: Early gene-expression profiling accurately predicts response to long-term treatment
A Randomized, Placebo-Controlled Study to Evaluate SRT2104, a Selective SIRT1 Activator, in Patients with Moderate to Severe Psoriasis
PubMed Full text in PMC Similar studies Analyze with GEO2R
Expression data from skin biopsy samples from patients with moderate-to-severe psoriasis
Effective treatment of psoriasis with etanercept is linked to suppression of IL17 signaling, not immediate response TNF
Psoriasis vulgaris ACCEPT cohort: paired lesional and non-lesional skin
PubMed Full text in PMC Similar studies GEO Profiles Analyze DataSet
Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor, PF 06700841, Reveal Reduction of Skin Inflammation in Plaque Psoriasis
Expression data from keratinocytes treated either with IL-22 or combination of tofacitinib (JAK1/3 inhibitor) and IL-22 at 6 hours
Guselkumab (interleukin-23-specific monoclonal antibody) demonstrates clinical and molecular response in moderate-to-severe psoriasis
Lesional and non-lesional skin gene-expression profiles from Phase-3 clinical trials of Brodalumab
Early quantification of systemic inflammatory (INF) and cardiovascular disease (CVD) proteins predicts long-term treatment response to Tofacitinib and Etanercept
Early quantification of systemic inflammatory (INF) and cardiovascular disease (CVD) proteins predicts long-term treatment response to Tofacitinib and Etanercept (INF data set)
Early quantification of systemic inflammatory (INF) and cardiovascular disease (CVD) proteins predicts long-term treatment response to Tofacitinib and Etanercept (CVD data set)
Tofacitinib blocks interferon-regulated biomarker genes in dermal and adventitial skin fibroblasts in early systemic sclerosis
PubMed Full text in PMC Similar studies
Gene expression profiling in psoriatic lesional and non-lesional skin [brodalumab treatment]
Psoriasis response to brodalumab: dose response and time course
PubMed Similar studies GEO Profiles Analyze DataSet
Treatment of granuloma annulare and suppression of pro-inflammatory cytokine activity with tofacitinib
PubMed Similar studies
Treatment of granuloma annulare and suppression of pro-inflammatory cytokine activity with tofacitinib [scRNA-Seq]
PubMed Similar studies SRA Run Selector
Treatment of granuloma annulare and suppression of pro-inflammatory cytokine activity with tofacitinib [RNA-Seq]
Oral JAK/SYK-inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in atopic dermatitis
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on